Avalo Therapeutics, Inc. (AVTX)
NASDAQ:AVTX
Total Valuation
Avalo Therapeutics has a market cap or net worth of $370.77M. The enterprise value is $170.32M.
Market Cap$370.77M
Enterprise Value$170.32M
Share Statistics
Avalo Therapeutics has 22,788,452 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,788,452
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Avalo Therapeutics’s return on equity (ROE) is -0.94 and return on invested capital (ROIC) is -70.18%.
Return on Equity (ROE)-0.94
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-70.18%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee2.57K
Profits Per Employee-3.40M
Employee Count23
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Avalo Therapeutics is ―. Avalo Therapeutics’s PEG ratio is -0.09.
PE Ratio―
PS Ratio4125.96
PB Ratio2.93
Price to Fair Value2.93
Price to FCF-4.73
Price to Operating Cash Flow-4.24
PEG Ratio-0.09
Income Statement
In the last 12 months, Avalo Therapeutics had revenue of 59.00K and earned -78.26M in profits. Earnings per share was -5.84.
Revenue59.00K
Gross Profit-285.00K
Operating Income-72.92M
Pretax Income-78.09M
Net Income-78.26M
EBITDA-72.92M
Earnings Per Share (EPS)-5.84
Cash Flow
In the last 12 months, operating cash flow was -51.46M and capital expenditures 0.00, giving a free cash flow of -51.46M billion.
Operating Cash Flow-51.46M
Free Cash Flow-51.46M
Free Cash Flow per Share-2.26
Dividends & Yields
Avalo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change196.36%
50-Day Moving Average15.54
200-Day Moving Average13.37
Relative Strength Index (RSI)54.62
Average Volume (3m)774.21K
Important Dates
Avalo Therapeutics upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Avalo Therapeutics as a current ratio of 8.14, with Debt / Equity ratio of 2.92%
Current Ratio8.14
Quick Ratio8.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.18
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Avalo Therapeutics has paid 165.00K in taxes.
Income Tax165.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Avalo Therapeutics EV to EBITDA ratio is -3.15, with an EV/FCF ratio of -4.47.
EV to Sales3.90K
EV to EBITDA-3.15
EV to Free Cash Flow-4.47
EV to Operating Cash Flow-4.47
Balance Sheet
Avalo Therapeutics has $98.34M in cash and marketable securities with $2.43M in debt, giving a net cash position of $95.91M billion.
Cash & Marketable Securities$98.34M
Total Debt$2.43M
Net Cash$95.91M
Net Cash Per Share$4.21
Tangible Book Value Per Share$5.41
Margins
Gross margin is 72.88%, with operating margin of -123601.69%, and net profit margin of -132642.37%.
Gross Margin72.88%
Operating Margin-123601.69%
Pretax Margin-132362.71%
Net Profit Margin-132642.37%
EBITDA Margin-123601.69%
EBIT Margin-123601.69%
Analyst Forecast
The average price target for Avalo Therapeutics is $41.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.75
Price Target Upside156.61% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-76.59%
EPS Growth Forecast94.03%